Printer Friendly

Oricula Therapeutics to launch volunteer human testing of novel, new hearing loss medicine, ORC-13661.

M2 EQUITYBITES-February 6, 2018-Oricula Therapeutics to launch volunteer human testing of novel, new hearing loss medicine, ORC-13661


Biotech company Oricula Therapeutics LLC stated on Monday that it will begin the volunteer human testing for safety, tolerability and pharmacokinetics of their novel, new medicine, ORC-13661, upon the US FDA permission.

Under the company's animal studies, ORC-13661 provided highly significant protection of hearing in rats exposed to high doses of aminoglycoside antibiotics, a common cause of human hearing loss.

Following the company's successful clinical trials, ORC-13661 may be the first US FDA-approved medicine to prevent hearing loss for patients undergoing aminoglycoside treatment.

In conjunction, the company is commercialising research conducted at the University of Washington and the Fred Hutchinson Cancer Research Center and holds an exclusive license to two extensive composition of matter patents.

The funding for the company's preclinical development was obtained through grants from the National Institutes of Health, including a USD2.1m grant from National Institute Of Allergy And Infectious Diseases.

((Comments on this story may be sent to

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Feb 6, 2018
Previous Article:Nets to delist shares from Nasdaq Copenhagen; Compulsory redemption of minority shareholders in Nets by Evergood 5 AS.
Next Article:Jernigan Capital acquires 100% membership interests of Jacksonville and Atlanta development properties for USD8.1m.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |